Minneapolis-based Preventice has received CE Mark approval for its remote cardiac monitoring technology called BodyGuardian. The system had previously received FDA clearance for tracking of non-lethal arrhythmias in ambulatory patients in the US.

BodyGuardian is a biomonitoring device, developed in collaboration with the Mayo Clinic, that uses a highly portable, lightweight, wearable sensor called the BodyGuardian Control Unit to help doctors constantly track one’s cardiac electric performance. This continuous cardiac ECG and rhythm monitoring keeps physicians informed of their patients’ states of health and warns them in case of an emergency. The non-intrusive sensor attached to the patient’s skin is in the form of a bandage, and allows patients to go about their day-to-day activities with little, if any, discomfort. Data from the BodyGuardian Control Unit is transferred to a BodyGuardian enabled smart phone, which in turn is delivered securely to Preventice’s cloud-based mobile health system called Preventice CarePlatform. The Preventice CarePlatform accumulates real-time data from user devices and sends them to healthcare professionals to enable constant monitoring of patients’ cardiac performance. Doctors and nurses can view emergency alerts and notifications regarding their patients on a computer or an iPad. Further, patient specific cardiac performance thresholds can be set, so that a physician receives an alert when that threshold is crossed. The stand-alone BodyGuardian system can monitor the ECG, heart rate, respiration rate, activity level and body position. The sensor can be coupled with other devices to also remotely monitor weight and blood pressure.

source:Preventice